Charles Torgbor

Charles Torgbor

Auto-generated profile, based on publicly available information

Charles Torgbor

Tufts University School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Science Signaling
Verified
Journal Article
Open access
KKKihyuck Kwak
Kihyuck Kwak
HSHaewon Sohn
Haewon Sohn
RGRachel George
Rachel George
CTCharles Torgbor
Charles Torgbor
JMJavier Manzella-Lapeira
Javier Manzella-Lapeira
SPSusan K. Pierce
Susan K. Pierce
The demand for a vaccine for coronavirus disease 2019 (COVID-19) highlighted gaps in our understanding of the requirements for B cell responses to antigens, particularly to membrane-presented antigens, as occurs in vivo. We found that human B cell responses to membrane-presented antigens required the function of Piezo1, a plasma membrane mechanosensitive cation channel. Simply making contact with a glass probe induced calcium (Ca 2+ ) fluxes in B cells that were blocked by the Piezo1 inhibitor GsMTx4. When placed on glass surfaces, the plasma membrane tension of B cells increased, which stimulated Ca 2+ influx and spreading of B cells over the glass surface, which was blocked by the Piezo1 inhibitor OB-1. B cell responses to membrane-presented antigens but not to soluble antigens were inhibited both by Piezo1 inhibitors and by siRNA-mediated knockdown of Piezo1. Thus, the activation of Piezo1 defines an essential event in B cell activation to membrane-presented antigens that may be exploited to improve the efficacy of vaccines.

3 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CTCharles Torgbor
Charles Torgbor
HSHaewon Sohn
Haewon Sohn
BDBrian L. P. Dizon
Brian L. P. Dizon
EMEvan C. Mutic
Evan C. Mutic
RGRachel George
Rachel George
SPSusan K. Pierce
Susan K. Pierce
B cell responses to membrane-presented antigens appear to be strongly favored over soluble antigens in vivo suggesting that vaccines that mimic membrane-presented antigens may be highly efficacious. We recently demonstrated that human B cell responses to membrane-associated but not to soluble antigens in vitro depended on the expression and activity of the plasma membrane mechanosensitive ion channel, Piezo1. Here, we provide evidence that the efficacy of the current human papillomavirus virus-like particle (HPV VLP) vaccines may be due in part to their inherent ability to mimic Piezo1-dependent membrane presentation of antigens to B cells. We compared HPV-specific human B cell responses to HPV VLPs versus soluble HPV pentameric capsomeres and showed that although both induced calcium responses, only HPV VLP-induced responses were blocked by Piezo1 inhibitors. The kinetics of internalization of HPV-VLP and capsomeres into HPV-specific B cells were similar and neither required Piezo1 function as shown by small interfering RNA (siRNA)-mediated knockdown of Piezo. However, trafficking of HPV-VLPs into intracellular major histocompatibility complex (MHC) class II, lysosomal associated membrane protein 1 (LAMP1) + antigen-processing compartments was Piezo1-dependent, whereas trafficking of capsomeres was not. In addition, a time course of intracellular trafficking suggested that colocalization of HPV-VLP with MHC classII was more stable over time as compared to capsomeres. Taken together these findings suggest that the ability of HPV-VLP vaccines to mimic Piezo1-dependent membrane antigen presentation may be exploited in the design of highly effective human vaccines.

19 August 2025 in Journal of Virology
Verified
Journal Article
Open access
CTCharles Torgbor
Charles Torgbor
DTDavid A. Thorley-Lawson
David A. Thorley-Lawson
AMAnn Moormann
Ann Moormann
The germinal center model (GCM) of Epstein-Barr virus (EBV) persistence in humans proposes that EBV infects and drives naïve B cells through the GC to establish a quiescent lifelong persistent infection in memory B cells. EBV causes several cancers, and the normal in vivo counterparts of major EBV-associated cancers have been identified in the GCM. Yet, the normal in vivo counterparts of immunosuppression-related/immunoblastic B-cell lymphoma (IL), which occurs in immunosuppressed transplant and HIV patients and resembles lymphoblastoid cell lines (LCLs), remain elusive. We performed a comparative analysis of human tonsillar B cells to identify the closest normal in vivo counterparts of ILs/LCLs. Here we show that EBV-infected tonsillar marginal zone (MZ) B cells, which are GC-independent, are the closest in vivo correlates of ILs/LCLs. Like LCLs, EBV-infected MZ B cells express the EBV growth program, which includes high expression of the oncogenic LMP1 and the DNA-mutating enzyme activation-induced cytidine deaminase (AID), in the absence of the transcription factor BCL6. Furthermore, these EBV-infected MZ B cells are proliferating extensively and are Ki67 + . AID expression, rapid proliferation, and LMP1 expression put these cells at high risk for tumor development. Of therapeutic importance, the high expression of LMP1 could prove to be the Achilles’ heel of IL/LCL-like EBV-infected MZ B cells to be targeted. Consequently, we now propose that there are two pathways of EBV persistence in vivo : (i) the established GC model and (ii) the GC-independent MZ model, and EBV-infected MZ B cells are plausibly the in vivo precursors of IL. IMPORTANCE: Epstein-Barr virus (EBV) causes several cancers, and the normal counterparts of major EBV-associated cancers have been identified in the germinal center model (GCM) of EBV persistence in humans. We searched for the normal in vivo counterparts of immunoblastic B-cell lymphoma (IL) that occurs in immunosuppressed individuals. IL resembles in vitro EBV-infected B cells driven by EBV to become indefinitely proliferating lymphoblastoid cell lines (LCLs). Here, we demonstrate that EBV-infected tonsillar marginal zone (MZ) B cells, which are GC-independent, are the in vivo correlates of LCLs/ILs and the plausible precursors of IL in humans. EBV-infected MZ B cells express the EBV growth program with high expression of the oncogenic LMP1 and the DNA-mutating enzyme AID and are proliferating extensively. AID expression, rapid proliferation, and LMP1 expression put these cells at high risk for cancer development. Clinical interventions that target LMP1-expressing MZ B cells should dramatically decrease the incidence of IL.